Maintenance alemtuzumab in refractory chronic lymphocytic leukaemia.
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2016
At a glance
- Drugs Alemtuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 19 Feb 2010 Actual number of patients (12) added as reported by ClinicalTrials.gov record.
- 19 Feb 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 11 Feb 2008 New trial record.